Pulmonary Tuberculosis Complicated with Severe Thrombocytopenia with Diffuse Alveolar Hemorrhaging during Anti-tuberculosis Chemotherapy: An Autopsy Report

Anti-tubercular therapy (ATT) induced thrombocytopenia: A systematic review

INTRODUCTION

Drug-induced thrombocytopenia is a known adverse event of several drugs. Antitubercular therapy (ATT) is rarely reported but important cause of thrombocytopenia. The present review aimed to understand the profile of thrombocytopenia caused by first-line ATT i.e. isoniazid, rifampicin, pyrazinamide, and ethambutol.

MATERIALS AND METHODS

We screened case reports, case series, and letter-to-editor from databases, like Pubmed/MEDLINE, Ovid, and EMBASE from 1970 to 2021. The PRISMA guidelines were followed in the present systematic review.

RESULTS

Categorical data were expressed as n (%) and quantitative data were expressed as median (IQR). After applying the inclusion/exclusion criteria, 17 case reports and 7 letters to the editor were selected for the present review. Rifampicin was most frequently associated with thrombocytopenia (65%). A median (IQR) drop to 20,000 (49,500) platelets/mm3 was observed. Anti-rifampicin associated antibodies and anti-dsDNA positivity were found in six studies. Except for two, all patients responded to symptomatic treatment.

DISCUSSION

ATT-induced thrombocytopenia can be life-threatening and require hospitalization. Clinicians should be aware of the association of ATT with thrombocytopenia and should take appropriate measures for patient management.

CONCLUSION

This review provides clinicians a comprehensive picture of adverse effects and their management in ATT induced thrombocytopenia.

Study of the association of interferon-γ gene polymorphisms and Th1/Th2 balance in tuberculosis susceptibility

OBJECTIVES

This study investigated and analyzed the association of interferon-γ (IFN-γ) gene polymorphisms and Th1/Th2 balance in tuberculosis susceptibility.

METHODS

From January 2018 to January 2020, 121 tuberculosis patients that were hospitalized for initial treatment and were chosen as the pulmonary tuberculosis group, and another 80 healthy individuals with physical examination in the same period were selected as the control group. The genetic distribution of IFN-γ +874 sites in the two sets of subjects was detected by sequence-specific primer PCR (PCR-SSP), the serum IFN-γ level was detected by ELISA, and the ratio of Th1 and Th2 on cells in two sets of subjects were detected by flow cytometry. Subsequently, we compared the differences in IFN-γ degree and the changes in Th1/Th2 in patients with different genotypes.

RESULTS

The difference in the distribution of IFN-γ (+874 T/A) genotype frequencies between the two groups of subjects was significantly different (P<0.05), and the frequency of A allele in the tuberculosis group was clearly higher than that in the control group (P<0.05). Compared with the control group, the Th1 cells percentage in the pulmonary tuberculosis group decreased remarkably, the Th2 cells percentage increased significantly, while the Th1/Th2 ratio was notably decreased (P<0.05). In addition, the Th1/Th2 ratio in tuberculosis patients with an IFN-γ (+874 T/A) genotype AA was remarkably lower than those with AT+TT genotype (P<0.05).

CONCLUSION

An AA genotype with IFN-γ (+874 T/A) is a susceptible genotype for tuberculosis. The mechanism may be related to the imbalance of Th1/Th2 which is more likely to occur in patients with AA genotype. This can lead to a decline in immune function of the body, making it more susceptible to infection with mycobacterium which induces tuberculosis.

The prevalence and risks of major comorbidities among inpatients with pulmonary tuberculosis in China from a gender and age perspective: a large-scale multicenter observational study

In clinical practice, PTB patients have concurrent many types of comorbidities such as pneumonia, liver disorder, diabetes mellitus, hematological disorder, and malnutrition. Detecting and treating specific comorbidities and preventing their development are important for PTB patients. However, the prevalence of most comorbid conditions in patients with PTB is not well described. We conducted a large-scale, multicenter, observational study to elucidate and illustrate the prevalence rates of major comorbidities in inpatients at 21 hospitals in China. The 19 specific comorbidities were selected for analysis in this patient cohort, and stratified the inpatient cohort according to age and gender. A total of 355,929 PTB inpatients were included, with a male:female ratio of 1.98 and the proportion of ≥ 65 years PTB inpatients was the most. Approximately 70% of PTB inpatients had at least one defined type of comorbidity. The prevalence of 19 specific comorbidities in inpatients with PTB was analyzed, with pneumonia being the most common comorbidity. The prevalence of most comorbidities was higher in males with PTB except thyroid disorders, mental health disorders, etc. The prevalence of defined most comorbidities in patients with PTB tended to increase with increasing age, although some specific comorbidities tended to increase initially then decrease with increasing age. Our study describes multiple clinically important comorbidities among PTB inpatients, and their prevalence between different gender and age groups. The results will enhance the clinical aptitude of physicians who treat patients with PTB to recognize, diagnose, and treat PTB comorbidities early.

Influenza Vaccination-associated Acute Thrombocytopenia and Diffuse Alveolar Hemorrhage

Influenza vaccination can trigger various adverse reactions, and thrombocytopenia is also rarely reported. Although patients with mild thrombocytopenia are sometimes asymptomatic, severe thrombocytopenia can cause severe bleeding. We herein report a rare case of severe thrombocytopenia that occurred within one day of influenza vaccination and diffuse alveolar hemorrhage (DAH) leading to acute respiratory failure. The patient was treated with glucocorticoid pulse therapy, intravenous immunoglobulin, and temporary mechanical ventilation, and eventually he made a full recovery. Vaccine-related thrombocytopenia and DAH should be considered adverse reactions, even if they develop very soon after vaccination.